Home Management of Patients with Moderate or Severe Respiratory Failure Secondary to COVID-19, Using Remote Monitoring and Oxygen with or without HFNC

Abstract

Background: Home treatment of patients affected by COVID-19 is still a matter of daily debate. During the clinical evolution of the disease, there are high risks of lung failure, which requires oxygen therapy. Here, we report our clinical experience with at-home treatment using high-flow nasal cannula in non-hospitalised patients with confirmed COVID-19. Patients and methods: In this study, 18 patients with moderate-to-severe respiratory failure secondary to COVID-19 were monitored at home daily for temperature and SpO2 measurements. Other parameters such as saturation of peripheral oxygen (SpO2), SpO2/FiO2 (fraction of inspired oxygen), temperature, and lung performance were monitored periodically. Depending on oxygen requirements, the patients also received either standard oxygen via a face mask or, if higher FiO2 required, high-flow nasal cannula (HFNC). Results: All 18 patients had favourable outcomes and recovered from COVID-19. No death was recorded in this group. Conclusion: Our clinical experience proves that high-flow nasal cannula oxygen therapy may be considered for at-home treatment of COVID-19 patients with moderate lung failure. This could be useful for further treatment during the pandemic and may also be considered in future epidemics.

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

“…This HA-reversal effect could account for sharp increases observed within 24 h after administration of IVM of pre-treatment depressed SpO2 levels in severe COVID-19 patients, as summarized in Figure 6 below, which reproduces a figure from the most recent of three clinical studies reporting this effect [ 64 ]. In contrast to the sharp, rapid increases in SpO2 levels observed in these studies, moderate and severe COVID-19 patients under standard care typically manifest decreasing SpO2 values in tandem with increasing pulmonary CT abnormalities from the day of onset of disease symptoms through the second week following, as established in several studies that tracked SpO2 values, pulmonary abnormalities, or both [ 65 , 66 , 67 , 68 , 69 , 70 , 71 ].…”

A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID- 19 Patients in Nigeria

“…In addition, Osman, et al and Annunziata, et al have documented changes in SpO 2 in non-ivermectin treated COVID-10 patients [24,25]. These two studies show unequivocally that there is an initial dip in SpO 2 towards day 8 before a recovery towards day 14.…”

A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody

“…In three studies using sensitive detection methods, antibodies against SARS-CoV-2 RBD or against spike S1 were observed in serum of most COVID-19 patients within a week of the onset of symptoms [ 185 , 186 , 187 ]. The most pronounced reductions in SpO2 in COVID-19 patients, however, typically occur at least a week following onset of symptoms [ 188 , 189 ]. Of course, some patients could experience breathing dysfunction early in the disease course, prior to the generation of antibodies, from causes other than hemagglutination.…”